In a recent interview, Jayme Heim, MSN, a Family Nurse Practitioner and Clinical Manager of the Psoriasis and Eczema Treatment Center, discussed various topics related to the advancements in dermatology, including teledermatology and artificial intelligence.
One of the areas of focus in dermatology is the treatment of hidradenitis suppurativa (HS) and other rare skin diseases. Heim mentioned that new medications, such as IL-17 inhibitors, are expected to be approved soon, providing additional options for patients with HS. In addition, the use of JAK inhibitors is being investigated as a potential treatment for HS. Current therapies, such as TNF inhibitors, are not always effective in controlling the disease, so the development of new therapies is crucial.
Heim also emphasized the importance of research in dermatology, not only for common skin diseases but also for orphan diseases that have been overlooked in the past. There are ongoing studies exploring new therapies for diseases like Behcet’s and vitiligo.
In terms of treatment modalities, dermatologists are exploring the use of oral forms of biologic therapies, moving away from injectables. This shift could offer more convenience and accessibility for patients.
Regarding the implementation of technology in dermatology, Heim acknowledged that there is still a long way to go. Although artificial intelligence and teledermatology hold promise, the physical examination of the skin remains crucial for accurate assessment. However, advancements in these technologies are being made and may complement traditional examinations in the future.
In conclusion, the field of dermatology is witnessing exciting developments in terms of new therapies and research. The approval of new medications, exploration of alternative treatments, and the integration of technology are all contributing to improved patient care and outcomes.
Sources:
– HCPLive (source article)
